Maria Sibilia - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Maria Sibilia

Showing results (111-120 of 113) with videos related to

Pageof 12

Sort By:

You have reached the last page of results.This site can display upto 113 results.

European Journal of Cancer (Oxford, England : 1990)|August 21, 2020

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.

Cancer Cell|September 15, 2012

EGF receptor is required for KRAS-induced pancreatic tumorigenesisChristine M Ardito, Barbara M Grüner, Kenneth K Takeuchi, et al.

The Journal of Experimental Medicine|February 24, 2018

ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signalingStefanie Schmidt, Neele Schumacher, Jeanette Schwarz, et al.

Pageof 12

Search research articles

Showing results (111-120 of 113) with videos related to

Sort By:

Pageof 12

You have reached the last page of results.This site can display upto 113 results.

European Journal of Cancer (Oxford, England : 1990)|August 21, 2020

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.

Cancer Cell|September 15, 2012

EGF receptor is required for KRAS-induced pancreatic tumorigenesisChristine M Ardito, Barbara M Grüner, Kenneth K Takeuchi, et al.

The Journal of Experimental Medicine|February 24, 2018

ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signalingStefanie Schmidt, Neele Schumacher, Jeanette Schwarz, et al.

Pageof 12